title: Heparin-bonded circuits: clinical outcomes and costs.
abstract: The aim of this study was to use meta-analysis to combine the results of numerous studies and examine the impact of heparin-bonded circuits on clinical outcomes and the resulting costs. Heparin-bonded circuits, both ionically and covalently bonded, are examined separately. The results of the study provide evidence that heparin-bonded circuits result in improved clinical outcomes when compared to the identical nonheparin-bonded circuits. These improved clinical outcomes result in subsequent lower costs per patient with their use. However, differences are apparent in the significance and magnitude of these outcomes between ionically and covalently bonded circuits. Covalently bonded circuits provide a greater magnitude and significance of improvement in clinical outcomes than ionically bonded circuits. Total cost savings can be expected to be three times greater with covalently bonded circuits ($3231 versus $1068). It was concluded that the choice regarding the use of a heparin-bonded circuits and the type of heparin-bonded circuit used has the potential to alter clinical outcomes and subsequent costs. Cost consideration cannot be ignored, but clinical benefits should be the main rationale for the choice of cardiopulmonary bypass circuit. This analysis provides evidence that clinical benefits and cost savings can both be derived from use of the same technology-covalently bonded circuits.
authors.affiliation: Industrial Relations Center, Carlson School of Management, University of Minnesota, Minneapolis 55455-0430, USA.
authors.forename: C B
authors.initials: CB
authors.lastname: Mahoney
mesh_terms: D001672:Biocompatible Materials; D002315:Cardiopulmonary Bypass / Q000191:economics / Q000295:instrumentation*; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003363:Cost Control; D003362:Cost-Benefit Analysis; D005112:Extracorporeal Circulation / Q000191:economics / Q000379:methods*; D017048:Health Care Costs; D006493:Heparin / Q000191:economics / Q000494:pharmacology*; D006801:Humans; D011183:Postoperative Complications / Q000517:prevention & control; D012995:Solubility; D055672:Static Electricity; D013499:Surface Properties; D016896:Treatment Outcome
chemical_list: D001672:Biocompatible Materials; D006493:Heparin